


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

2-Hydroxyethoxyethylated Bases as Acyclic Analogues of 1,5-Anhydrohexitol Nucleoside Derivatives

A. Van Aerschot^{ab}; Z. Ni^a; J. Rozenski^a; P. Claes^a; E. De Clercq^a; P. Herdewijn^a

^a Rega Institute for Medical Research, Laboratory of Medicinal Chemistry, Katholieke Universiteit Leuven, Leuven, Belgium ^b Shanghai Institute of Planned Parenthood Research, China

To cite this Article Van Aerschot, A. , Ni, Z. , Rozenski, J. , Claes, P. , De Clercq, E. and Herdewijn, P.(1994) '2-Hydroxyethoxyethylated Bases as Acyclic Analogues of 1,5-Anhydrohexitol Nucleoside Derivatives', *Nucleosides, Nucleotides and Nucleic Acids*, 13: 8, 1791 — 1800

To link to this Article: DOI: 10.1080/15257779408009481

URL: <http://dx.doi.org/10.1080/15257779408009481>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

2-HYDROXYETHOXYETHYLATED BASES AS ACYCLIC ANALOGUES OF 1,5-
ANHYDROHexitol NUCLEOSIDE DERIVATIVES

A. Van Aerschot*, Ni Zhigang[†], J. Rozenski, P. Claes, E. De Clercq and
P. Herdewijn

Rega Institute for Medical Research, Laboratory of Medicinal Chemistry,
Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven,
Belgium





Abstract : *The synthesis and antiviral activity of a new series of acyclic nucleoside analogues containing a (2-hydroxyethoxy)ethyl moiety is discussed.*

We recently reported the discovery of a new class of nucleoside analogues endowed with interesting antiviral properties and based on a 1,5-anhydrohexitol ring as the carbohydrate fragment^{1,2}. Since then several efforts have been undertaken to broaden our knowledge of this new class of antiviral nucleosides and to have a better insight into the structure-activity relationship. As 1,5-anhydrohexitol nucleosides differ from natural 2'-deoxynucleosides by a methylene group inserted between O-4' and C-1' and considering that acyclovir is a non-toxic, biologically active acyclic nucleoside analogue, an obvious approach to modify these anhydrohexitol nucleosides was to cut off the lower part of the tetrahydropyran moiety, leaving only the 2-hydroxyethoxyethyl moiety. This communication deals with the synthesis and activity of these simple acyclic analogues.

Results and discussion

Monotritylation of diethyleneglycol 1 was accomplished with 1 eq of tritylchloride in pyridine in 42 % isolated yield after column chromatography on silica gel (CH₂Cl₂; CH₂Cl₂-MeOH 95:5). Mesylation

* On leave from Shanghai Institute of Planned Parenthood Research, China.



1. R = R' = H

2. R = Ph₃C, R' = H (42 %)

3. R = Ph₃C, R' = CH₃SO₂ (100 %)

4-11 a, b

a. R = Ph₃C

b. R = H

4. B = uracil-1-yl

5. B = cytosin-1-yl

6. B = 5-iodouracil-1-yl

7. B = 5-bromouracil-1-yl

8. B = adenin-9-yl

9. B = 2-amino-6-chloropurin-7-yl

10. B = 2-amino-6-chloropurin-9-yl

11. B = guanin-9-yl

(1.5 eq) of **2** in CH₂Cl₂ in the presence of 1.6 eq of triethylamine gave quantitative conversion to **3** and after extraction, the crude product was considered to be of sufficient purity to be used directly for the alkylation reactions. Alkylation of uracil, cytosine and adenine proceeded in a straightforward manner under the conditions³ described in TABLE 1.

TABLE 1. Reaction conditions for alkylation of the heterocyclic bases and elution solvents (CH_2Cl_2 -MeOH) for chromatographic purification on silica gel.

Heterocyclic base	3	Additive + reaction conditions	obtained product (elution solvens)	detritylated product (elution solvens)
uracil 1.2 eq	1 eq	K_2CO_3 2.5 eq KI 1.2 eq 20 h 90°C	34 % 4a (97:3)	89 % 4b (95:5)
cytosine 1.2 eq	1 eq	CsCO_3 2 eq 20 h 80°C	40 % 5a (97:3)	90 % 5b (95:5 → 85:15)
adenine 1.5 eq	1 eq	NaH 1.4 eq 20 h 90°C	28 % 8b (95:5, losses on purification)	89 % 8b (95:5 → 85:15)
2-NH ₂ ,6-Cl purine 1.2 eq	1 eq	K_2CO_3 1.3 eq 20 h 90°C	34 % 10a 13 % 9a (98:2)	80 % 10b (95:5 → 80:20)

Assignment of the alkylation site of cytosine was based on NMR and UV data, which were in agreement with the literature⁴. Direct alkylation of the sodium salt of 5-iodouracil⁵ gave low yield of the desired product. Therefore 6b was prepared from the uracil analogue 4a (45 % yield, elution conditions CH_2Cl_2 -MeOH 95:5), after treatment with iodine in the presence of Ce(IV)ammonium nitrate^{6,7} which proceeded with concomitant detritylation (FIG. 1). Bromination of 4a with bromine in pyridine⁸, followed by detritylation, afforded 57 % of 7b (chromatographic purification CH_2Cl_2 -MeOH 95:5).

Alkylation of 2-amino-6-chloropurine (1.25 eq) with 3 in the presence of potassium carbonate (1.3 eq) in anhydrous DMF gave 34 % of 10a and 13 % of the N⁷-isomer 9a, which were distinguished by UV⁹ and NMR¹⁰⁻¹². The compounds 4a-10a were detritylated with 80 % aqueous HOAc for 1-2 h at 80°C and purified on silica gel. Conversion of 10b to 11b was accomplished in 55 % yield by treatment with adenosine deaminase¹³ for 40 h at 30°C followed by HPLC purification on a polystyrene divinylbenzene column (RoGel RP 7 nm 10 μM , 250x25 mm, BioRad). A gradient was used of MeOH in water with solvens A containing H₂O-MeOH 98:2 and B containing H₂O-MeOH 15:85. The sample had to be dissolved in MeOH and therefore the chromatography was

started at very low MeOH concentration with a gradient from 0 to 40 % B in 25 min followed by 40 to 100 % B in 25 min at 8 mL/min. Elution was obtained at approximately 65 % B¹⁴.

The 2-(hydroxyethoxy)ethyl analogues 4b-8b and 4b were evaluated for their activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), vaccinia virus, vesicular stomatitis virus, Coxsackie virus B4, polio virus-1, parainfluenza-3 virus, reovirus-1, Sindbis virus and Semliki forest virus.

Only the guanine derivative 11b displayed marginal activity, without any apparent cytotoxicity, against HSV-1 (minimal effective concentration : 20 µg/mL, which equals 80 µM) in embryonic skin-muscle cells (E₆SM). This marginal activity (50 µM in Vero cells) likewise was reported by the Wellcome Research Laboratories when studying acyclic analogues of acyclovir¹⁵. However, neither analytical details nor synthetic strategies were described in the Wellcome report. The remaining acyclic derivatives described in this manuscript, have not been reported anywhere else before.

Acknowledgements

This study was supported partially by a grant of the Belgian N.F.W.O. (Nationaal Fonds voor Wetenschappelijk Onderzoek) (Project n° 3.0096.91). Arthur Van Aerschot is a Research Associate of the Belgian National Fund of Scientific Research. We thank Dr. G. Janssen for coordinating the mass spectra analysis. We thank Mieke Vandekinderen for editorial and Anita Van Lierde for technical assistance.

References

1. Van Aerschot, A.; Verheggen, I. and Herdewijn, P. *Bioorganic & Medicinal Chemistry Letters* 3, 1013-1018 (1993).
2. Verheggen, I.; Van Aerschot, A.; Toppet, S.; Snoeck, R.; Janssen, G.; Balzarini, J.; De Clercq, E. and Herdewijn, P. *J. Med. Chem.* 36, 2033-2040 (1993).
3. Huryn, D.M.; Sluboski, B.C.; Tam, S.Y.; Weigele, M.; Sim, I.; Anderson, B.A.; Mitsuya, H. and Broder, S. *J. Med. Chem.* 35, 2347-2354 (1992).

4. Bronson, J.J.; Ghazzouli, I.; Hitchcock, M.J.M.; Webb, R.R. and Martin, J.C. *J. Med. Chem.* **32**, 1457-1463 (1989).
5. Colla, L.; Busson, R.; De Clercq, E. and Vanderhaeghe, H. *Eur. J. Med. Chem. - Chim. Ther.* **17**, 569-576 (1982).
6. Asakura, J.-i. and Robins, M.J. *Tetrahedron Letters* **29**, 2855-2858 (1988).
7. Asakura, J.-i. and Robins, M.J. *J. Org. Chem.* **55**, 4928-4933 (1990).
8. Lin, T.-S.; Chen, M.S.; McLaren, C.; Gao, Y.-S.; Ghazzouli, I. and Prusoff, W.H. *J. Med. Chem.* **30**, 440-444 (1987).
9. Ashton, W.T.; Canning Meurer, L.; Cantone, C.L.; Field, A.; Hannah, J.; Karkas, J.D.; Liou, R.; Patel, G.F.; Perry, H.C.; Wagner, A.F.; Walton, E. and Tolman, R.L. *J. Med. Chem.* **31**, 2304-2315 (1988).
10. Haines, D.R.; Tseng, C.K.H. and Marquez, V.E. *J. Med. Chem.* **30**, 943-947 (1987).
11. Chenon, M.-T.; Pugmire, R.J.; Grant, D.M.; Panzica, R.P. and Townsend, L.B. *J. Am. Chem. Soc.* **97**, 4627-4637 (1975).
12. Kjellberg, J. and Johansson, N.G. *Tetrahedron* **42**, 6541-6544 (1986).
13. Robins, M.J. and Hatfield, P.W. *Can. J. Chem.* **60**, 547-553 (1982).
14. All final compounds were fully analyzed by UV, NMR and high resolution MS and were homogeneous by TLC. Full analytical details can be obtained on request at the authors address.
15. Keller, P.M.; Fyfe, J.A.; Beauchamp, L.; Lubbers, C.M.; Furman, P.A.; Schaeffer, H.J. and Elion, G.B. *Biochemical Pharmacology* **30**, 3071-3077 (1981).

SUPPLEMENTARY PAGES

N¹-[2-(Trityloxyethoxy)ethyl]uracil (4a)

UV (MeOH) λ_{max} 235 and 267 nm

¹H NMR (CHCl₃) δ 3.15 (t, 2H), 3.44-3.68 (m, 4H), 3.82 (dd, 2H), 5.45 (d, J=7.7 Hz, 1H), 7.10-7.42 (m, 17 H)

¹³C NMR (CDCl₃) δ 48.1, 62.8, 68.7, 70.5, 86.4, 101.0, 126.8, 127.5, 128.4, 143.6, 145.9, 150.8, 164.2 ppm.

MS-LSIMS (thioglycerol + NaCl) 465 (M + Na), 243 (Trityl), 221 (M-trityl).

N¹-[2-(hydroxyethoxy)ethyl]uracil (4b)

mp (MeOH - Et₂O) 100°C

UV (MeOH) λ_{max} 266 (10.200) nm

¹H NMR (DMSO-d₆) δ 3.43 (m, 4H), 3.60 (t, J=4.8 Hz, 2H), 3.80 (t, J=4.8 Hz, 2H), 4.57 (t, J=4.4 Hz, 1H, 4'-OH), 5.51 (d, J=7.5 Hz, 1H), 7.57 (d, J=7.8 Hz, 1H), 11.2 (br s, 1H) ppm.

¹³C NMR (DMSO-d₆) δ 47.2, 60.2, 67.9, 72.2, 100.4, 146.3, 151.0, 163.8 ppm.

HRMS - CI(C₄H₁₀) calculated for C₈H₁₃N₂O₄ 201.0875, found 201.0856.

N¹-[2-(Trityloxyethoxy)ethyl]cytosine (5a)

UV (MeOH) λ_{max} 234, 274 nm

¹H NMR (DMSO-d₆) δ 3.13 (t, 2H), 3.57 (t, 2H), 3.71 (m, 2H), 3.90 (m, 2H), 5.65 (d, J=7.3 Hz, 1H), 7.10-7.53 (m, 17H) ppm.

¹³C NMR (DMSO-d₆) δ 48.7, 62.6, 68.5, 69.9, 85.8, 92.9, 126.5, 127.3, 128.1, 143.6, 146.1, 153.0, 165.8 ppm.

MS-LSIMS (thioglycerol + NaCl) 464 (M + Na), 243 (trityl), 220 (M-trityl)

N¹-[2-(hydroxyethoxy)ethyl]cytosine (5b)

mp (MeOH) 150°C

UV (MeOH) λ_{max} 275 (9400), λ_{min} 253 nm

¹H NMR (DMSO-d₆) δ 3.44 (m, 4H), 3.60 (t, J=4.4 Hz, 2H), 3.77 (t, J=4.7 Hz, 2H), 5.64 (d, J=7.3 Hz, 1H), 7.00 (br s, NH₂), 7.51 (d, J=7.3 Hz, 1H) ppm.

¹³C NMR (DMSO-d₆) δ 48.4, 60.2, 68.3, 72.2, 92.9, 146.8, 155.9, 166.1 ppm.

MS-LSIMS (glycerol) 491 (M₂H + glycerol), 399 (2M + H), 292 (MH + glycerol), 200 (100 %, M+H)

HRMS calculated for C₈H₁₄N₃O₃ 200.1036, found 200.1018.

N¹-[2-(hydroxyethoxy)ethyl]-5-iodouracil (6b)

mp (MeOH - Et₂O) 92°C

UV (MeOH) λ_{max} 287 (br, 7650), λ_{min} 246 nm

¹H NMR (DMSO-d₆) δ 3.45 (s, 4H), 3.58 (t, J=5 Hz, 2H), 3.84 (t, J=5 Hz, 2H), 4.55 (br s, 1H), 8.10 (s, 1H, H-6) ppm.

¹³C NMR (DMSO-d₆) δ 47.2, 60.1, 67.4, 67.7, 72.1, 150.5, 150.6, 161.0 ppm.

HRMS-CI (iC₄H₁₀) calculated for C₈H₁₂IN₂O₄ (M + H) 326.9842, found 326.9830.

N¹-[2-(hydroxyethoxy)ethyl]-5-bromouracil (7b)

mp (MeOH-toluene) 130-131°C

UV (MeOH) λ_{max} 282 (8900), λ_{min} 243 nm.

¹H NMR (DMSO-d₆) δ 3.43 (br s, 4H), 3.62 (t, J=4.8 Hz, 2H), 3.82 (t, J=4.8 Hz, 2H), 4.60 (br s, 1H), 8.12 (s, 1H) ppm.

¹³C NMR (DMSO-d₆) δ 48.0, 60.5, 68.1, 72.4, 94.6, 146.4, 150.7, 158.6 ppm.

MS-LSIMS (thioglycerol) 279 (M + H), 199 (M - Br).

HRMS calculated for C₈H₁₂BrN₂O₄ 278.9980, found 278.9977.

N⁹-[2-(trityloxyethoxy)ethyl]adenine (8a)

UV (MeOH) λ_{max} 232, 261 nm.

¹H NMR (DMSO-d₆) δ 3.01 (t, J=4 Hz, 2H), 3.57 (t, J=4 Hz, 2H), 3.85 (t, J=4.7 Hz, 2H), 4.37 (t, J=4.7 Hz, 2H), 7.14-7.42 (m, 15H), 8.13, 8.15 (2 x s, 2H) ppm.

¹³C NMR (DMSO-d₆) δ 43.0, 63.0, 68.6, 69.6, 85.9, 118.7, 126.9, 128.2, 141.8, 143.8, 149.6, 152.4, 156.0 ppm.

MS-CI (iC₄H₁₀) 466 (M + H), 243 (trityl)

N⁹-[2-(hydroxyethoxy)ethyl]adenine (8b)

mp (MeOH-Et₂O) 162°C

UV (MeOH) $\lambda_{\max}$ 261 (13.900) nm.

^1H NMR (DMSO- d_6) δ 3.46 (m, 4H), 3.78 (t, $J=5.3$ Hz, 2H), 4.30 (t, $J=5.2$ Hz, 2H), 4.63 (t, 4'-OH, 1H), 7.19 (br s, 2H), 8.12, 8.15 (2 x s, 2H) (H2, H8) ppm.

^{13}C NMR (DMSO- d_6) δ 43.5, 60.6, 68.8, 72.4, 118.8, 142.2, 149.9, 152.9, 156.1 ppm.

MS-LSIMS (glycerol) 316 (M + H + glycerol), 224 (100 %, M + H), 136 (B + 2H).

HRMS calculated for $\text{C}_9\text{H}_{14}\text{N}_5\text{O}_2$ 224.1147, found 224.1137.

N⁹-[2-(trityloxyethoxy)ethyl]-2-amino-6-chloropurine (10a)

UV (MeOH) $\lambda_{\max}$ 309 nm.

^1H NMR (CDCl_3) δ 3.20 (t, $J=6$ Hz, 2H), 3.60 (t, $J=6$ Hz, 2H), 3.81 (t, $J=5$ Hz, 2H), 4.26 (t, $J=5.4$ Hz, 2H), 5.30 (br s, NH_2), 7.15-7.50 (m, 15H), 7.90 (s, 1H, H-8) ppm.

^{13}C NMR (CDCl_3) δ 43.6, 63.1, 68.8, 70.7, 86.5, 125.5, 126.8, 127.6, 128.4, 143.3, 143.7, 150.9, 153.5, 158.9 ppm.

MS-CI (iC_4H_{10}) 500 (M + H), 256 (M - trityl), 243 (trityl).

N⁷-[2-(trityloxyethoxy)ethyl]-2-amino-6-chloropurine (9a)

UV (MeOH) $\lambda_{\max}$ 319 nm, $\lambda_{\min}$ 275 nm.

^1H NMR (DMSO- d_6) δ 3.00 (t, 2H), 3.56 (t, 2H), 3.82 (t, 2H), 4.52 (t, 2H), 6.60 (s, 2H, NH_2), 7.15-7.45 (m, 15H), 8.33 (s, 1H) ppm.

^{13}C NMR (DMSO- d_6) δ 46.3, 63.0, 69.3, 69.7, 85.9 (Ph_3C), 114.8, 126.9, 127.8, 128.2, 143.5, 143.7, 150.0, 159.9 ppm.

MS-CI (iC_4H_{10}) 500 (M + H), 256 (M-trityl), 243 (trityl).

N⁹-[2-(hydroxyethoxy)ethyl]guanine (11b)

mp (H_2O -MeOH) 218°C

UV (MeOH) $\lambda_{\max}$ 254 (13.100), 271 (sh, 9000) nm.

^1H NMR (DMSO- d_6) δ 3.46 (br s, 4H), 3.72 (t, $J=5.2$ Hz, 2H), 4.11 (t,

J=5.0 Hz, 2H), 6.63 (br s, 2H, NH₂), 7.69 (s, 1H, H8) ppm.

¹³C NMR (DMSO-d₆) δ 43.2, 60.6, 69.0, 72.5, 116.8, 138.9, 151.9, 154.3, 158.3 ppm.

MS-LSIMS (thioglycerol) 240 (M + H), 152 (B + 2H)

HRMS calculated for C₉H₁₄N₅O₃ 240.1097, found 240.1097.

Received 12/22/93

Accepted 3/8/94